SUMMARY The response of neonatal tremor to a suckling stimulation test was investigated in 102 healthy neonates born at full term. In 84 the tremor resolved immediately; none had hypocalcaemia and only one had mild hypoglycemia. Eighteen in whom the tremor continued had either hypocalcaemia (n=13) or hypoglycaemia (n=5).
Patients and methods
Of 9408 newborn infants born at the Hadassah Medical Centre between August 1984 and February 1988, 143 were found to have neonatal tremor at the routine physical examination carried out during the first 72 hours of life and before the morning meal. Neonatal tremor was defined as repetitive movements of both hands (with or without movement of the legs or jaws) at a frequency of 2-5/s and lasting more than 10 minutes. A total of 102 infants who fulfilled the following criteria were included in the study: gestational age >37 weeks; birth weight -2500 g; Apgar score >s8 at five minutes, and a physical examination that was otherwise normal. Forty one neonates were excluded from the study because they were premature, or small for gestational age, or had diabetic mothers, or Ethamsylate (diethylammonium 2,5-dihydroxybenzenesulphonate) is a non-steroidal drug that reduces bleeding from small vessels. The results of a double blind multicentre study showed that there were fewer severe periventricular haemorrhages among the survivors of a group of very low birthweight infants treated with this drug shortly after birth.1 The mode of action remains to be clearly elucidated but experimental evidence shows an inhibition of the products of the prostaglandin pathway.2 A group of very low birthweight infants with respiratory distress syndrome treated with ethamsylate had lower serum concentrations of immunoreactive prostacyclin metabolite than an untreated control group,3 and one interpretation was that the drug limited prostacyclin release from ischaemic brain, perhaps preventing bleeding secondary to the presence of this potent vasodilating and platelet disaggregating substance.
Prostaglandins are known to play a part in cerebral blood flow. Indomethacin inhibits prostaglandin production although at a different enzymatic point than that thought to be affected by ethamsylate. Studies in animals, adult humans, and babies attest to the reduction in cerebral blood flow velocity after treatment with indomethacin. 4 Although inhibition of the prostaglandins produced by metabolism of arachidonic acid are not as complete after treatment with ethamsylate as after treatment with indomethacin, it seems plausible that this drug may also reduce cerebral blood flow velocity in the newborn. Periventricular haemorrhages develop early in postnatal life in most infants, therefore a common approach to prevention entails prophylactic administration of the drug to a cohort of babies defined as 'high risk'. Sixty per cent of very low birthweight infants will be given treatment for a condition that they will never develop if this approach is adopted; proposed agents therefore need to be fully investigated. 
